Explainer
How flu vaccine strains are chosen each year
Flu vaccines are updated regularly because influenza viruses evolve continuously.[1] WHO recommends strains each February for the northern hemisphere and each September for the southern, leaving about 6-8 months to make, approve and ship vaccines; national regulators such as the FDA and the EMA then set the composition for their own markets.[2][3]
This explainer covers how flu vaccine strains are selected and made. It is not medical advice. Which vaccine suits you is a question for a clinician or pharmacist, and national health agencies publish who is eligible each season.
Unlike many vaccines, seasonal flu vaccines have to be reviewed and updated regularly, because circulating influenza viruses evolve continuously.[1] The process runs on a fixed calendar. WHO issues a global recommendation, and national regulators then decide what goes into the vaccines sold in their markets.[2][3]
The WHO meetings in February and September
Twice a year, WHO gathers experts to look at which flu viruses are spreading and to choose the strains for the next vaccines. The February meeting picks strains for the northern hemisphere’s winter, and the September meeting picks for the southern hemisphere’s. The timing gives manufacturers about 6 to 8 months to make, approve and deliver the vaccines.[2][4]
WHO usually makes its recommendation in February for the next northern hemisphere season and in September for the next southern hemisphere season, chosen to leave about 6-8 months for production, regulatory approval and distribution.[2] The evidence comes from the Global Influenza Surveillance and Response System (GISRS), a network of 165 institutions in 135 countries.[5] The consultations weigh surveillance data, antigenic tests using ferret antisera and sera from vaccinated people, gene sequencing, virus fitness forecasts, antiviral susceptibility, vaccine effectiveness and the availability of candidate vaccine viruses.[6][4] Haemagglutinin (HA) is the main vaccine antigen. Recommendations name a “-like” virus so that manufacturers can use antigenically similar candidate viruses.[7]
From global advice to national decisions: the FDA and the EMA
After WHO’s recommendation, national or regional authorities approve the composition and formulation of vaccines and set policy on their use.[3] In the US, the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) votes on the strains. FDA’s Center for Biologics Evaluation and Research then advises manufacturers, who update their licensed vaccines through strain change supplements.[8] On 12 March 2026, VRBPAC voted 7-0 for each of the two 2026-27 formulations WHO had proposed, and the FDA issued its recommendations the next day.[9][10]
In the EU, the European Medicines Agency issues composition recommendations every year based on WHO’s observations. The 2026/27 recommendations were endorsed by its CHMP committee in March 2026, and makers of centrally authorised vaccines had until 15 June 2026 to apply to change their composition.[11] The EMA’s list was amended twice in May 2026 and ended up matching WHO’s strains.[12][13]
Egg-based, cell-based and recombinant vaccines
Most flu vaccines are still made by growing the virus in hens’ eggs.[14] Some are grown in cells in a lab instead.[15] Recombinant vaccines skip growing the virus altogether and use no eggs.[16] Because viruses can change slightly when grown in eggs, WHO sometimes picks a slightly different strain for egg-based vaccines than for cell-based ones.[17]
Egg-based manufacturing remains the most common method worldwide.[14] The FDA approved a cell culture-based process in 2012, and since 2019-20 all viruses for the US cell-based vaccine have been grown only in cells.[15] Recombinant vaccines, on the US market since 2013, use no eggs and need no candidate vaccine virus.[16] Viruses may replicate differently in eggs and cells, and egg-adaptive changes can alter antigenicity, so WHO sometimes recommends separate viruses for each system.[17] For 2026-27, every available egg isolate of the new B/Victoria subclades had lost a glycosylation site, and antisera against the egg-grown virus recognised circulating viruses less well than antisera against the cell-grown virus.[18] mRNA vaccines are another non-egg platform: the FDA approved Moderna’s mFLUSIVA in August 2026 (see how mRNA vaccines work and the mRNA vaccines tracker).[19]
From four strains to three: the end of B/Yamagata
No circulating B/Yamagata lineage virus has been confirmed since March 2020, and the EMA says the lineage is no longer considered a public health threat.[20] The EU’s 2026/27 recommendation includes no B/Yamagata strain. Where quadrivalent vaccines are still required, makers of inactivated vaccines may add the older B/Phuket/3073/2013 strain.[21] In the US, the CDC says the entire projected 2026-27 supply is trivalent.[22]
Why the match varies
The CDC says how well flu vaccines work can vary from season to season.[23] Strains are picked about 6-8 months ahead, and the viruses keep evolving in the meantime.[2][1] The 2025-26 northern hemisphere season shows the effect. An A(H3N2) variant called subclade K was identified in late 2025 and classified as J.2.4.1 in October 2025, before being renamed.[24] By early 2026 it predominated in many countries and was poorly recognised by antibodies against the 2025-26 vaccine strains.[25][26] Interim US estimates put 2025-26 vaccine effectiveness against hospitalisation at 41% in children and 30% in adults.[27] The same CDC report described subclade K as an antigenically drifted virus that made up 93% of genetically characterised US H3N2 samples.[28]
H3N2 drift remains a recurring problem. At the March 2026 VRBPAC meeting, members discussed putting two H3N2 strains in future vaccines and noted the regulatory hurdles for licensing such four-strain vaccines.[29]
For the 2026-27 composition and how this season is unfolding, read the 2026-27 flu season tracker next. For flu symptoms and when to seek care, see the flu explainer.
Read next
Next in the crash course
Flu season 2026-27 tracker: vaccine strains, subclade K, surveillance
The 2026-27 northern hemisphere flu season: WHO, FDA and EMA vaccine strains, the subclade K H3N2 concern, and US and EU surveillance to 13 November.
Questions readers ask
Who decides what goes into the flu vaccine?
WHO makes a global recommendation using data from its surveillance network. National or regional authorities, such as the FDA in the US and the EMA in the EU, then approve the composition for their markets.[5][3][8][11]
When are the strains chosen?
WHO usually recommends strains in February for the northern hemisphere and in September for the southern hemisphere, about 6-8 months before vaccines are needed.[2]
Why do egg-based and cell-based vaccines sometimes use different strains?
Flu viruses can change when grown in eggs, so WHO sometimes picks different but antigenically similar viruses for each production system.[17]
Why are flu vaccines now three-strain rather than four-strain?
No circulating B/Yamagata virus has been confirmed since March 2020, so neither WHO nor the EMA recommends a B/Yamagata strain for 2026-27. The CDC says the entire projected US supply for 2026-27 is trivalent.[20][21][22]
Why does the flu vaccine work better in some years than others?
The CDC says effectiveness varies from season to season. In 2025-26, the H3N2 subclade K virus drifted away from the vaccine strain, and interim US effectiveness against hospitalisation was 41% in children and 30% in adults.[23][28][27]
Do recombinant vaccines need eggs?
No. Recombinant flu vaccines use no chicken eggs and need no candidate vaccine virus to produce.[16]
Sources
· 29 claims from 8 publishers
Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.
- [1]
Unlike many vaccines, seasonal flu vaccines must be evaluated and updated regularly because circulating influenza viruses evolve continuously. confirmedas of 2026-02-27
- Questions and answers: recommended composition of influenza virus vaccines for the northern hemisphere 2026-2027 season · World Health Organization · Primary source · 2026-02-27 · Question 1 (retrieved 2026-11-07)
- [2]
WHO usually makes its vaccine composition recommendations in February for the next northern hemisphere season and in September for the next southern hemisphere season, timed to allow about 6-8 months for production, regulatory approval and distribution. confirmedas of 2026-02-27
- Questions and answers: recommended composition of influenza virus vaccines for the northern hemisphere 2026-2027 season · World Health Organization · Primary source · 2026-02-27 · Question 1 (retrieved 2026-11-07)
- Questions and answers: recommended composition of influenza virus vaccines for the northern hemisphere 2026-2027 season · World Health Organization · Primary source · 2026-02-27 · Question 1 (retrieved 2026-11-07)
- [3]
After WHO's global recommendation, national or regional authorities approve the composition and formulation of flu vaccines and set policy on their use. confirmedas of 2026-02-27
- Questions and answers: recommended composition of influenza virus vaccines for the northern hemisphere 2026-2027 season · World Health Organization · Primary source · 2026-02-27 · Question 10 (retrieved 2026-11-07)
- [4]
The evidence is evaluated at WHO consultations held each February and September, with experts from WHO collaborating centres, regulatory laboratories, national influenza centres and academic institutions. confirmedas of 2026-02-27
- Questions and answers: recommended composition of influenza virus vaccines for the northern hemisphere 2026-2027 season · World Health Organization · Primary source · 2026-02-27 · Question 3 (retrieved 2026-11-07)
- Questions and answers: recommended composition of influenza virus vaccines for the northern hemisphere 2026-2027 season · World Health Organization · Primary source · 2026-02-27 · Q3 (PDF) (retrieved 2026-11-07)
- [5]
WHO's Global Influenza Surveillance and Response System (GISRS) is a network of 165 public health institutions in 135 countries that supplies the data behind the recommendations. confirmedas of 2026-02-27
- Questions and answers: recommended composition of influenza virus vaccines for the northern hemisphere 2026-2027 season · World Health Organization · Primary source · 2026-02-27 · Question 2 (retrieved 2026-11-07)
- FDA briefing document: VRBPAC March 12, 2026, strain composition of influenza virus vaccines for the 2026-2027 season · US Food and Drug Administration · Primary source · 2026-03-10 · Background, p. 2 (retrieved 2026-11-07)
- [6]
The WHO consultations weigh surveillance data, antigenic tests with ferret antisera and vaccinated people's sera, gene sequencing, virus fitness forecasts, antiviral susceptibility, vaccine effectiveness and the availability of candidate vaccine viruses. confirmedas of 2026-02-27
- Questions and answers: recommended composition of influenza virus vaccines for the northern hemisphere 2026-2027 season · World Health Organization · Primary source · 2026-02-27 · Question 3 (retrieved 2026-11-07)
- Questions and answers: recommended composition of influenza virus vaccines for the northern hemisphere 2026-2027 season · World Health Organization · Primary source · 2026-02-27 · Question 3 (retrieved 2026-11-07)
- [7]
Haemagglutinin (HA) is the main antigen in seasonal flu vaccines, and a "-like virus" recommendation lets manufacturers use antigenically similar candidate vaccine viruses. confirmedas of 2026-02-27
- Questions and answers: recommended composition of influenza virus vaccines for the northern hemisphere 2026-2027 season · World Health Organization · Primary source · 2026-02-27 · Question 4 (retrieved 2026-11-07)
- Questions and answers: recommended composition of influenza virus vaccines for the northern hemisphere 2026-2027 season · World Health Organization · Primary source · 2026-02-27 · Question 8 (retrieved 2026-11-07)
- [8]
In the US, after VRBPAC's recommendations, FDA's Center for Biologics Evaluation and Research advises manufacturers on strain composition, and makers update their licensed vaccines through strain change supplements. confirmedas of 2026-03-10
- FDA briefing document: VRBPAC March 12, 2026, strain composition of influenza virus vaccines for the 2026-2027 season · US Food and Drug Administration · Primary source · 2026-03-10 · Regulatory Pathway, p. 4 (retrieved 2026-11-07)
- FDA briefing document: VRBPAC March 12, 2026, strain composition of influenza virus vaccines for the 2026-2027 season · US Food and Drug Administration · Primary source · 2026-03-10 · Regulatory Pathway, p. 4 (retrieved 2026-11-07)
- [9]
On 12 March 2026 the FDA's VRBPAC voted 7-0 for the WHO-recommended egg-based strains and 7-0 for the cell- and recombinant-based strains for US 2026-27 vaccines. confirmedas of 2026-03-12
- Summary minutes, 191st Vaccines and Related Biological Products Advisory Committee meeting, March 12, 2026 · US Food and Drug Administration · Primary source · Voting Questions 1 and 2 (retrieved 2026-11-07)
- FDA vaccine advisers recommend adding subclade K to fall shots · CIDRAP (University of Minnesota) · Secondary source · 2026-03-12 (retrieved 2026-11-07)
- Summary minutes, 191st Vaccines and Related Biological Products Advisory Committee meeting, March 12, 2026 · US Food and Drug Administration · Primary source · Voting questions (PDF) (retrieved 2026-11-07)
- [10]
The FDA made its 2026-27 US flu vaccine composition recommendations on 13 March 2026, and the CDC lists the same egg-based and cell or recombinant strains as WHO. confirmedas of 2026-09-29
- 2026-2027 Flu Season · US Centers for Disease Control and Prevention · Primary source · 2026-09-29 · Vaccine composition (verified in browser 2026-11-07) (retrieved 2026-11-07)
- [11]
The European Medicines Agency issues EU flu vaccine composition recommendations every year based on WHO's observations; the 2026/27 recommendations were endorsed by its CHMP committee in March 2026, with change applications for centrally authorised vaccines due by 15 June 2026. confirmedas of 2026-05-26
- EU recommendations for 2026/2027 seasonal flu vaccine composition · European Medicines Agency · Primary source · 2026-03-30 (retrieved 2026-11-07)
- EU recommendations for 2026/2027 seasonal flu vaccine composition · European Medicines Agency · Primary source · 2026-03-30 (retrieved 2026-11-07)
- [12]
The EMA first published its 2026/27 recommendation on 30 March 2026, added egg-derived and live attenuated strains on 7 May, and added the cell-derived H3N2 strain and the live attenuated B strain on 26 May. confirmedas of 2026-05-26
- EU recommendations for 2026/2027 seasonal flu vaccine composition · European Medicines Agency · Primary source · 2026-03-30 (retrieved 2026-11-07)
- EU recommendations for 2026/2027 seasonal flu vaccine composition · European Medicines Agency · Primary source · 2026-03-30 (retrieved 2026-11-07)
- [13]
The EMA's final 2026/27 EU recommendation, amended twice in May 2026, matches WHO's strains, including A/Darwin/1454/2025 for egg-based and live attenuated vaccines and A/Darwin/1415/2025 for cell-based vaccines. confirmedas of 2026-05-26
- EU recommendations for 2026/2027 seasonal flu vaccine composition · European Medicines Agency · Primary source · 2026-03-30 (retrieved 2026-11-07)
- EU recommendations for 2026/2027 seasonal flu vaccine composition · European Medicines Agency · Primary source · 2026-03-30 (retrieved 2026-11-07)
- [14]
The CDC says egg-based manufacturing is the most common way flu vaccines are made and has been used for more than 70 years; WHO says most vaccines produced globally use egg-based processes. confirmedas of 2026-11-07
- How flu vaccines are made · US Centers for Disease Control and Prevention · Primary source · Egg-based (verified in browser 2026-11-07) (retrieved 2026-11-07)
- Questions and answers: recommended composition of influenza virus vaccines for the northern hemisphere 2026-2027 season · World Health Organization · Primary source · 2026-02-27 · Question 3 (retrieved 2026-11-07)
- [15]
The FDA approved a cell culture-based flu vaccine production process in 2012, and since the 2019-20 season all viruses for the US cell-based vaccine have been grown only in cell culture. confirmedas of 2026-11-07
- How flu vaccines are made · US Centers for Disease Control and Prevention · Primary source · Cell-based (verified in browser 2026-11-07) (retrieved 2026-11-07)
- How flu vaccines are made · US Centers for Disease Control and Prevention · Primary source · Cell-based (verified in browser 2026-11-07) (retrieved 2026-11-07)
- [16]
Recombinant flu vaccines, approved for the US market in 2013, use no chicken eggs and need no candidate vaccine virus to produce. confirmedas of 2026-11-07
- How flu vaccines are made · US Centers for Disease Control and Prevention · Primary source · Recombinant (verified in browser 2026-11-07) (retrieved 2026-11-07)
- How flu vaccines are made · US Centers for Disease Control and Prevention · Primary source · Recombinant (verified in browser 2026-11-07) (retrieved 2026-11-07)
- Questions and answers: recommended composition of influenza virus vaccines for the northern hemisphere 2026-2027 season · World Health Organization · Primary source · 2026-02-27 · Question 3 (retrieved 2026-11-07)
- [17]
Flu viruses can change when grown in eggs, so WHO sometimes recommends different but antigenically similar viruses for egg-based and cell-based vaccines. confirmedas of 2026-02-27
- Questions and answers: recommended composition of influenza virus vaccines for the northern hemisphere 2026-2027 season · World Health Organization · Primary source · 2026-02-27 · Question 9 (retrieved 2026-11-07)
- FDA briefing document: VRBPAC March 12, 2026, strain composition of influenza virus vaccines for the 2026-2027 season · US Food and Drug Administration · Primary source · 2026-03-10 · p. 3 (retrieved 2026-11-07)
- [18]
For 2026-27, all available egg-grown isolates of the new B/Victoria subclades lost a glycosylation site, so antisera against the egg-grown virus recognised circulating viruses less well than antisera against the cell-grown equivalent. confirmedas of 2026-02-27
- Recommended composition of influenza virus vaccines for use in the 2026-2027 northern hemisphere influenza season (full report) · World Health Organization · Primary source · 2026-02-27 · Conclusions, influenza B (retrieved 2026-11-07)
- [19]
In August 2026 the FDA approved Moderna's mFLUSIVA (mRNA-1010) for adults 50 and older, the first mRNA-based influenza vaccine and Moderna's fourth FDA-approved product after Spikevax, mRESVIA and mNEXSPIKE. confirmedas of 2026-08-06
- Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA · Moderna (press release) · Primary source · 2026-08-06 (retrieved 2026-10-10)
- FDA Approves Moderna's mRNA Flu Vaccine After Phase 3 Success · AJMC · Secondary source · 2026-08-06 (retrieved 2026-10-10)
- [20]
There have been no confirmed detections of circulating B/Yamagata lineage viruses since March 2020. confirmedas of 2026-02-27
- Recommended composition of influenza virus vaccines for use in the 2026-2027 northern hemisphere influenza season (full report) · World Health Organization · Primary source · 2026-02-27 · Influenza B (retrieved 2026-11-07)
- EU recommendations for 2026/2027 seasonal flu vaccine composition · European Medicines Agency · Primary source · 2026-03-30 (retrieved 2026-11-07)
- [21]
The EU 2026/27 recommendation includes no B/Yamagata strain; where quadrivalent vaccines are still required, makers of inactivated vaccines may add the earlier B/Phuket/3073/2013 B/Yamagata strain. confirmedas of 2026-05-26
- EU recommendations for 2026/2027 seasonal flu vaccine composition · European Medicines Agency · Primary source · 2026-03-30 (retrieved 2026-11-07)
- EU recommendations for 2026/2027 seasonal flu vaccine composition · European Medicines Agency · Primary source · 2026-03-30 (retrieved 2026-11-07)
- [22]
The CDC says 100% of the projected US flu vaccine supply for 2026-27 is trivalent (three-component). confirmedas of 2026-09-29
- 2026-2027 Flu Season · US Centers for Disease Control and Prevention · Primary source · 2026-09-29 · Vaccine supply (verified in browser 2026-11-07) (retrieved 2026-11-07)
- [23]
The CDC says how well flu vaccines work can vary from season to season. confirmedas of 2026-11-07
- How well flu vaccines work · US Centers for Disease Control and Prevention · Primary source · 2024-08-14 · Overview (verified in browser 2026-11-07) (retrieved 2026-11-07)
- [24]
Subclade K viruses are seasonal A(H3N2) viruses that emerged from the J.2.4 subclade; they were first classed as J.2.4.1 in October 2025 and then renamed subclade K. confirmedas of 2026-02-27
- Questions and answers: recommended composition of influenza virus vaccines for the northern hemisphere 2026-2027 season · World Health Organization · Primary source · 2026-02-27 · Question 7 (retrieved 2026-11-07)
- Questions and answers: recommended composition of influenza virus vaccines for the northern hemisphere 2026-2027 season · World Health Organization · Primary source · 2026-02-27 · Q7 (PDF; the preceding sentence dates it to after the September 2025 recommendation) (retrieved 2026-11-07)
- [25]
Between September 2025 and January 2026, subclade K viruses were detected in all regions and predominated in many countries. confirmedas of 2026-02-27
- Recommended composition of influenza virus vaccines for use in the 2026-2027 northern hemisphere influenza season (full report) · World Health Organization · Primary source · 2026-02-27 · Influenza A(H3N2) (retrieved 2026-11-07)
- [26]
The FDA's March 2026 briefing said subclade K viruses were poorly recognised by antibodies against the 2025-26 northern hemisphere vaccine strains, while antisera against the subclade K Darwin viruses recognised them better. confirmedas of 2026-03-10
- FDA briefing document: VRBPAC March 12, 2026, strain composition of influenza virus vaccines for the 2026-2027 season · US Food and Drug Administration · Primary source · 2026-03-10 · p. 2 (retrieved 2026-11-07)
- Recommended composition of influenza virus vaccines for use in the 2026-2027 northern hemisphere influenza season (full report) · World Health Organization · Primary source · 2026-02-27 · Conclusions (retrieved 2026-11-07)
- [27]
Interim CDC estimates for 2025-26 put vaccine effectiveness at 38-41% against outpatient flu visits and 41% against hospitalisation in children, and 22-34% and 30% in adults. confirmedas of 2026-03-12
- Interim Estimates of 2025-26 Seasonal Influenza Vaccine Effectiveness - United States, September 2025-February 2026 · US Centers for Disease Control and Prevention (MMWR) · Primary source · 2026-03-12 · Summary (verified in browser 2026-11-07) (retrieved 2026-11-07)
- FDA vaccine advisers recommend adding subclade K to fall shots · CIDRAP (University of Minnesota) · Secondary source · 2026-03-12 (retrieved 2026-11-07)
- FDA vaccine advisers recommend adding subclade K to fall shots · CIDRAP (University of Minnesota) · Secondary source · 2026-03-12 · Article body (retrieved 2026-11-07)
- [28]
The CDC's interim 2025-26 report said 93% of genetically characterised US A(H3N2) samples were subclade K, an antigenically drifted virus. confirmedas of 2026-03-12
- Interim Estimates of 2025-26 Seasonal Influenza Vaccine Effectiveness - United States, September 2025-February 2026 · US Centers for Disease Control and Prevention (MMWR) · Primary source · 2026-03-12 · Introduction (verified in browser 2026-11-07) (retrieved 2026-11-07)
- [29]
At the March 2026 VRBPAC meeting, members discussed putting two A(H3N2) strains in future flu vaccines to address ongoing antigenic drift, and acknowledged the regulatory challenges of licensing such four-strain vaccines. confirmedas of 2026-03-12
- Summary minutes, 191st Vaccines and Related Biological Products Advisory Committee meeting, March 12, 2026 · US Food and Drug Administration · Primary source · Meeting Summary, p. 3 (retrieved 2026-11-07)
- Summary minutes, 191st Vaccines and Related Biological Products Advisory Committee meeting, March 12, 2026 · US Food and Drug Administration · Primary source · Meeting summary (PDF) (retrieved 2026-11-07)
Revision history (1)
- Page created.
Created Nov 7, 2026. Last reviewed by an editor on Nov 8, 2026. Next scheduled review: Mar 15, 2027.
Cite this page
"How flu vaccine strains are chosen each year." ContentLora, updated Nov 7, 2026. https://contentlora.com/explain/how-flu-vaccines-are-chosen
Spotted an error? Suggest a correction or emailcorrections@contentlora.com.